secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0000950170-25-016678
Event type: litigation
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome settles AUVELITY patent litigation with Teva; generic entry no earlier than 2038-2039
--------------------------------------------------------------------------------

- Settlement grants Teva license to sell generic AUVELITY starting Mar 31, 2039 (if pediatric exclusivity) or Sep 30, 2038 (if not).
- All ongoing AUVELITY patent litigation in U.S. District Court for New Jersey will be terminated.
- Agreement is subject to review by the U.S. FTC and U.S. Department of Justice.
- CEO Herriot Tabuteau says settlement reflects strength of Axsome’s IP portfolio and commitment to CNS innovation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/0000950170-25-016678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/axsm-20250210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-016678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer